Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Elicio Therapeutics Inc. (ELTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ELTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 76.31% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 129.26M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 2 | Beta 2.16 | 52 Weeks Range 3.70 - 9.99 | Updated Date 07/12/2025 |
52 Weeks Range 3.70 - 9.99 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -108.03% | Return on Equity (TTM) -744.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 116695566 | Price to Sales(TTM) - |
Enterprise Value 116695566 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.61 | Shares Outstanding 15997000 | Shares Floating 10299137 |
Shares Outstanding 15997000 | Shares Floating 10299137 | ||
Percent Insiders 45.12 | Percent Institutions 10.45 |
Upturn AI SWOT
Elicio Therapeutics Inc.
Company Overview
History and Background
Elicio Therapeutics, founded in 2011, is a clinical-stage biotechnology company developing immunotherapies based on its Amphiphile technology platform. It aims to enhance cancer treatment through targeted immune activation.
Core Business Areas
- Amphiphile Technology Platform: Elicio's core business revolves around its Amphiphile technology, which delivers immunogens directly to the lymphatic system to enhance T cell and antibody responses.
- Cancer Immunotherapies: The company develops novel immunotherapies for various cancers, including metastatic melanoma and KRAS-driven tumors, focusing on improved efficacy and safety compared to existing treatments.
Leadership and Structure
The leadership team includes Robert Connelly (CEO), Peter DeMuth (Chief Medical Officer) and other experienced professionals. The organizational structure is typical of a biotech company, with departments focused on R&D, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- ELI-002 2P: An investigational Amphiphile vaccine designed to target KRAS-driven tumors. Currently in clinical trials (Phase 1/2). Competitors include companies developing similar KRAS-targeting therapies, such as Mirati Therapeutics(MRTX, acquired by BMS) and Amgen (AMGN) with their KRAS G12C inhibitor Sotorasib. No direct market share at this stage as it's investigational
- ELI-007: An investigational Amphiphile vaccine targeting mKRAS-driven solid tumors. Currently in clinical trials (Phase 1/2). Similar competitive landscape to ELI-002 2P. No direct market share at this stage as it's investigational.
Market Dynamics
Industry Overview
The cancer immunotherapy market is rapidly growing, driven by advances in understanding the immune system and the development of novel therapeutic approaches like personalized vaccines and checkpoint inhibitors. There is an increasing demand for effective and safe cancer treatments.
Positioning
Elicio Therapeutics is positioned as an innovator in cancer immunotherapy, leveraging its Amphiphile technology to deliver targeted immunotherapies. Its competitive advantage lies in its ability to enhance immune responses and potentially overcome limitations of existing therapies.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is estimated to be in the tens of billions of dollars and growing. Elicio is targeting specific subsets of cancers, particularly those driven by KRAS mutations, which represent a significant unmet need. Their position depends on clinical trial success.
Upturn SWOT Analysis
Strengths
- Novel Amphiphile technology platform
- Targeted delivery of immunogens to the lymphatic system
- Promising preclinical and clinical data
- Experienced leadership team
- Focus on unmet needs in cancer therapy
Weaknesses
- Clinical-stage company with no commercial products yet
- High dependence on successful clinical trial outcomes
- Requires substantial funding for R&D and clinical development
- Limited brand recognition compared to larger pharmaceutical companies
Opportunities
- Potential for breakthrough therapies in cancer treatment
- Strategic partnerships with larger pharmaceutical companies
- Expansion of the Amphiphile technology to other disease areas
- Positive clinical trial data leading to accelerated approval pathways
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in the competitive landscape
- Difficulty in securing sufficient funding
Competitors and Market Share
Key Competitors
- MRTX
- AMGN
- BNTX
- GILD
Competitive Landscape
Elicio Therapeutics faces competition from larger pharmaceutical companies with established cancer immunotherapy portfolios. Its Amphiphile technology offers a potential advantage in terms of targeted delivery and enhanced immune response.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical research, clinical trial initiation, and platform development. No significant revenue at this time.
Future Projections: Future growth depends on successful clinical trial outcomes and potential regulatory approvals. Analyst projections are speculative at this stage.
Recent Initiatives: Focus on advancing ELI-002 2P and ELI-007 clinical programs, expanding the Amphiphile technology platform.
Summary
Elicio Therapeutics is a clinical-stage biotech company with a novel Amphiphile technology. Its success is highly dependent on positive clinical trial outcomes. It faces competition from larger pharma companies, but its innovative approach offers potential advantages. Securing sufficient funding for R&D is critical for future growth, but it is in a novel and growing market of cancer vaccines.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- ClinicalTrials.gov
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elicio Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-02-05 | CEO, President & Director Mr. Robert T. Connelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://elicio.com |
Full time employees 32 | Website https://elicio.com | ||
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.